Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients

Journal of the Neurological Sciences

Volumn 287, Issue 1-2, 2009, Pages 64-68

  Yuan, Rey Yue ^a   Sheu, Jau Jiuan ^a   Yu, Jia Ming ^a   Hu, Chaur Jong ^a   Tseng, Ing Jy ^b   Ho, Chun Sum ^a   Yeh, Ching Ying ^c   Hung, Ya Lin ^a   Chiang, Tsuey Ru ^d  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

A1298C; C677T; Homocysteine; MTHFR; Parkinson's disease; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BENSERAZIDE PLUS LEVODOPA; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; VITAMIN BLOOD LEVEL;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIPARKINSON AGENTS; BASE SEQUENCE; BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD+); PARKINSON DISEASE; POLYMORPHISM, GENETIC; SEX DISTRIBUTION;

EID: 70350622591     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.09.007     Document Type: Article

References (36)

1. Hankey G.J., and Eikelboom J.W. Homocysteine and vascular disease. Lancet 354 (1999) 407-413
2. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346 (2002) 2007-2008
3. Allain P., Le Bouil A., Cordillet E., Le Quay L., Bagheri H., and Montastruc J.L. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 16 (1995) 527-529
4. Kuhn W., Roebroek R., Blom H., van Oppenraaij D., and Muller T. Hyperhomocysteinaemia in Parkinson's disease. J Neurol 245 (1998) 811-812
5. Kuhn W., Roebroek R., Blom H., van Oppenraaij D., Przuntek H., Kretschmer A., et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 40 (1998) 225-227
6. Muller T., Werne B., Fowler B., and Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 354 (1999) 126-127
7. Muller T., and Kuhn W. Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nat Clin Pract Neuro 3 (2007) E1
8. Blandini F., Fancellu R., Martignoni E., Mangiagalli A., Pacchetti C., Samuele A., et al. Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin Chem 47 (2001) 1102-1104
9. Muller T., Woitalla D., Hauptmann B., Fowler B., and Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 308 (2001) 54-56
10. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
11. Weisberg I.S., Jacques P.F., Selhub J., Bostom A.G., Chen Z., Curtis Ellison R., et al. The 1298A- > C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156 (2001) 409-415
12. Castro R., Rivera I., Ravasco P., Jakobs C., Blom H.J., Camilo M.E., et al. 5, 10-Methylenetetrahydrofolate reductase 677C- > T and 1298A- > C mutations are genetic determinants of elevated homocysteine. QJM 96 (2003) 297-303
13. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
14. Yasui K., Kowa H., Nakaso K., Takeshima T., and Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55 (2000) 437-440
15. Kuhn W., Hummel T., Woitalla D., and Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 56 (2001) 281 author reply-2
16. Brattstrom L. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 56 (2001) 281 author reply-2
17. Woitalla D., Kuhn W., and Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm Suppl (2004) 15-20
18. Religa D., Czyzewski K., Styczynska M., Peplonska B., Lokk J., Chodakowska-Zebrowska M., et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 404 (2006) 56-60
19. Todorovic Z., Dzoljic E., Novakovic I., Mirkovic D., Stojanovic R., Nesic Z., et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 248 (2006) 56-61
20. Camicioli R.M., Bouchard T.P., and Somerville M.J. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord 24 (2009) 176-182
21. Caccamo D., Gorgone G., Curro M., Parisi G., Di Iorio W., Menichetti C., et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med 9 (2007) 249-254
22. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
23. Kara I., Sazci A., Ergul E., Kaya G., and Kilic G. Association of the C677T and A1298C polymorphisms in the 5, 10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res 111 (2003) 84-90
24. Miller J.W., Selhub J., Nadeau M.R., Thomas C.A., Feldman R.G., and Wolf P.A. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60 (2003) 1125-1129
25. Zoccolella S., Lamberti P., Armenise E., de Mari M., Lamberti S.V., Mastronardi R., et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 11 (2005) 131-133
26. Yasui K., Nakaso K., Kowa H., Takeshima T., and Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 108 (2003) 66-67
27. O'Suilleabhain P.E., Bottiglieri T., Dewey Jr. R.B., Sharma S., and Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 19 (2004) 1403-1408
28. O'Suilleabhain P., and Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem?. Arch Neurol 61 (2004) 633-634
29. Lamberti P., Zoccolella S., Armenise E., Lamberti S.V., Fraddosio A., de Mari M., et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 12 (2005) 365-368
30. Postuma R.B., Espay A.J., Zadikoff C., Suchowersky O., Martin W.R., Lafontaine A.L., et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66 (2006) 1941-1943
31. Nakaso K., Yasui K., Kowa H., Kusumi M., Ueda K., Yoshimoto Y., et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207 (2003) 19-23
32. Rogers J.D., Sanchez-Saffon A., Frol A.B., and Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa. Association with vascular disease. Arch Neurol 60 (2003) 59-64
33. O'Suilleabhain P.E., Sung V., Hernandez C., Lacritz L., Dewey R.J., Bottiglieri T., et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61 (2004) 865-868
34. Zoccolella S., Lamberti P., Iliceto G., Diroma C., Armenise E., Defazio G., et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 43 (2005) 1107-1110
35. Ozer F., Meral H., Hanoglu L., Aydemir T., Yilsen M., Cetin S., et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 28 (2006) 853-858
36. Zoccolella S., Iliceto G., deMari M., Livrea P., and Lamberti P. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review. Clin Chem Lab Med 45 (2007) 1607-1613